Clinical TrialsThe ongoing registrational-intent study for ACR-368 has shown a 62.5% overall response rate in OncoSignature positive patients with endometrial cancer, highlighting its effectiveness.
Financial PositionAcrivon has a strong cash position with $202.8 million on the balance sheet, which is expected to support its operations until the second half of 2026, ensuring financial stability.
Research And DevelopmentThe dual WEE1/PKMYT1 inhibitor, ACR-2316, has demonstrated significant anti-tumor activity in preclinical models and has dosed its first patient ahead of schedule in a Phase 1 trial, marking a promising advancement in the pipeline.